Previous Close | 236.00 |
Open | 239.17 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 234.20 - 240.24 |
52 Week Range | 234.20 - 323.78 |
Volume | |
Avg. Volume | 10,539 |
Market Cap | 188.574B |
Beta (5Y Monthly) | 0.15 |
PE Ratio (TTM) | 15.13 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 10.86 (4.62%) |
Ex-Dividend Date | Mar 14, 2024 |
1y Target Est | N/A |
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
Q1 2024 Sarepta Therapeutics Inc Earnings Call
Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.